474 related articles for article (PubMed ID: 30756285)
1. Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.
Berghuis AMS; van Deurzen CHM; Koffijberg H; Terstappen LWMM; Sleijfer S; IJzerman MJ
Breast Cancer Res Treat; 2019 Jun; 175(2):451-458. PubMed ID: 30756285
[TBL] [Abstract][Full Text] [Related]
2. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
3. Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands.
van Dooijeweert C; Deckers IAG; Baas IO; van der Wall E; van Diest PJ
Breast Cancer Res Treat; 2019 Jun; 175(2):487-497. PubMed ID: 30825048
[TBL] [Abstract][Full Text] [Related]
4. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
Allott EH; Geradts J; Sun X; Cohen SM; Zirpoli GR; Khoury T; Bshara W; Chen M; Sherman ME; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
Breast Cancer Res; 2016 Jun; 18(1):68. PubMed ID: 27349894
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
[TBL] [Abstract][Full Text] [Related]
7. Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experience.
Slostad JA; Yun NK; Schad AE; Warrior S; Fogg LF; Rao R
Cancer Med; 2022 Dec; 11(24):4954-4965. PubMed ID: 35733293
[TBL] [Abstract][Full Text] [Related]
8. The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer.
Vogel C; Malter W; Morgenstern B; Ludwig S; Vehreschild JJ; Hamacher S; Mallmann P; Kirn V; Thangarajah F
Anticancer Res; 2019 May; 39(5):2647-2659. PubMed ID: 31092464
[TBL] [Abstract][Full Text] [Related]
9. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.
Curtit E; Nerich V; Mansi L; Chaigneau L; Cals L; Villanueva C; Bazan F; Montcuquet P; Meneveau N; Perrin S; Algros MP; Pivot X
Oncologist; 2013 Jun; 18(6):667-74. PubMed ID: 23723333
[TBL] [Abstract][Full Text] [Related]
10. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.
Halilovic A; Bulte J; Jacobs Y; Braam H; van Cleef P; Schlooz-Vries M; Werner A; Boelens O; Nagtegaal I; de Wilt H; Bult P
J Clin Pathol; 2017 Sep; 70(9):781-786. PubMed ID: 28325747
[TBL] [Abstract][Full Text] [Related]
11. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
Kaidar-Person O; Meattini I; Jain P; Bult P; Simone N; Kindts I; Steffens R; Weltens C; Navarria P; Belkacemi Y; Lopez-Guerra J; Livi L; Baumert BG; Vieites B; Limon D; Kurman N; Ko K; Yu JB; Chiang V; Poortmans P; Zagar T
Breast Cancer Res Treat; 2018 Jan; 167(2):479-483. PubMed ID: 28975433
[TBL] [Abstract][Full Text] [Related]
12. Biomarker Discordances and Alterations Observed in Breast Cancer Treated with Neoadjuvant Chemotherapy: Causes, Frequencies, and Clinical Significances.
Yilmaz C; Cavdar DK
Curr Oncol; 2022 Dec; 29(12):9695-9710. PubMed ID: 36547175
[TBL] [Abstract][Full Text] [Related]
13. Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients.
Nguyen TH; Nguyen VH; Nguyen TL; Qiuyin C; Phung TH
Biomed Res Int; 2019; 2019():7391237. PubMed ID: 31583246
[TBL] [Abstract][Full Text] [Related]
14. Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy.
Ongaro E; Gerratana L; Cinausero M; Pelizzari G; Poletto E; Giangreco M; Andreetta C; Pizzolitto S; Di Loreto C; Minisini AM; Mansutti M; Russo S; Fasola G; Puglisi F
Future Oncol; 2018 Apr; 14(9):849-859. PubMed ID: 29527957
[TBL] [Abstract][Full Text] [Related]
15. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients.
Dodson A; Parry S; Ibrahim M; Bartlett JM; Pinder S; Dowsett M; Miller K
J Pathol Clin Res; 2018 Oct; 4(4):262-273. PubMed ID: 30066480
[TBL] [Abstract][Full Text] [Related]
17. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
[TBL] [Abstract][Full Text] [Related]
19. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.
Walter V; Fischer C; Deutsch TM; Ersing C; Nees J; Schütz F; Fremd C; Grischke EM; Sinn P; Brucker SY; Schneeweiss A; Hartkopf AD; Wallwiener M
Breast Cancer Res Treat; 2020 Aug; 183(1):137-144. PubMed ID: 32613540
[TBL] [Abstract][Full Text] [Related]
20. Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
Chapman JA; Sgroi DC; Goss PE; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Badovinac-Crnjevic T; Shepherd LE; Pollak MN
Breast Cancer Res Treat; 2016 May; 157(1):101-8. PubMed ID: 27116182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
